PPARG and myeloid sarcoma: Of interest, n-3 PUFAs have demonstrated an ability to inhibit both IL-17 and IFNγ production in MS pathology, together with activation of PPARγ, but whether this results in inhibiting Th17.1 cell activation has not been demonstrated [198].